| Catalog Number: | 930-MSM4 |
|---|---|
| Reactivity: | |
| Gene: | |
| Host: |
Trial Size Available
Carrier-Free Available
Flow cytometry of lymphocyte gated PBMCs stained with CD19 monoclonal antibody (PDR134) (red) or isotype control (gray) followed by goat anti-mouse CF640R (red).
| Document Name | |
|---|---|
| Datasheet | Download Here |
| Material Safety Data Sheet | Download Here |
| Applications | Tested Dilutions | Protocol | Note |
|---|---|---|---|
| Flow Cytometry (Flow) | 1-2ug/million cells | Flow Cytometry Protocol | |
| Immunofluorescence (IF) | 1-3ug/ml | ||
| Western Blot (WB) | 2-4ug/ml | Western Blot Protocol |
4
1
5
3
6
3
2
CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.
Should a NeoBiotechnologies antibody not meet the experimental expectations outlined on our website or datasheet, please contact our Technical Support. We unconditionally guarantee our product.
Our team of scientists are ready to help you with expert recommendations or technical assistance related to applications or product use.
Information
© 2026 NeoBiotechnologies. All Rights Reserved.
Monday-Friday: 8:00am – 8:00pm Pacific Time
